Eikon Therapeutics integrates advanced engineering, single-molecule tracking and high-performance computing to visualize protein movement in living cells and accelerate drug discovery. Its clinical portfolio is anchored by EIK1001, a systemically administered TLR7/8 co-agonist now in Phase III for advanced melanoma, alongside EIK1003 (a PARP1 inhibitor in Phase 1) and EIK1004 (a CNS-penetrant PARP1-selective inhibitor poised to enter Phase 1 for brain cancers). The company is also advancing earlier-stage candidates, including two androgen receptor antagonists and an internally derived WRN inhibitor (EIK1005) for MSI-high and other DNA repair–deficient cancers. Clinical studies are operating in 28 countries across five continents, and Eikon says it is expanding R&D and building a fully integrated, 21st-century biotechnology company. Financially, Eikon announced the initial closing of a $350.7 million Series D and has privately raised in excess of $1.1 billion since its 2019 founding. Eikon operates facilities in California, New Jersey, and New York. Eikon Therapeutics integrates engineering and science to discover and advance drug candidates using its proprietary AI-powered Single Molecule Tracking (SMT) technology. The company’s internally developed programs focus on preclinical candidates in oncology, immunology, and neurologic disease. Eikon has expanded its pipeline by acquiring global rights to clinical-stage TLR7/8 agonists, licensing PARP1-selective inhibitors, and acquiring preclinical assets addressing protein homeostasis, DNA damage repair, and chromatin remodeling. Its clinical team has deep experience in advancing programs through regulatory review, and Eikon intends to use its SMT instruments to inform clinical-trial design and program decisions. Financially, Eikon completed a first close of a Series C equity financing that added nearly $106 million and has raised nearly $775 million in total capital since its founding in late 2019. Eikon Therapeutics builds a drug-discovery platform centered on super-resolution fluorescence microscopy, single-particle tracking and the quantitative data those microscopes generate. The company is focused on industrializing that platform to run high-throughput, live-cell drug screens and to reveal new biology and drug targets. Eikon is pursuing four unnamed target programs and has one undisclosed partner. Leadership and scale-up are priorities: the company plans to grow its roughly 100-person team (with an aim to double headcount) and has made multiple senior hires while operating under the oversight of Roger Perlmutter. Management says the platform is already running drug screens around the clock and generating high volumes of quantitative protein-dynamics data. Financially, Eikon has raised a large Series B and has accumulated over $668 million in total disclosed financing. Eikon Therapeutics has developed a live-cell super-resolution microscopy platform that measures the real-time movement of individual proteins in living cells to inform drug discovery. The platform evolved from Nobel Prize–winning work in super-resolution microscopy by Eric Betzig and collaborators and was industrialized by founders Betzig, Xavier Darzacq, Luke Lavis, and Robert Tjian. Eikon combines physics, engineering, chemistry, biology, automation, machine learning, and high-performance computing to apply protein-dynamics measurements across the drug discovery process. The company aims to translate these biological insights into differentiated therapeutics for unmet medical needs. Eikon is based in Hayward, Calif., and recently closed a $148 million Series A financing. The company also announced the appointment of Roger M. Perlmutter as its Chief Executive Officer and maintains a multidisciplinary scientific advisory board and leadership team to advance its platform.

Total raised

$1.1B

Funding rounds

4

Latest round

Series D

Latest activity

Feb 2025